PURPOSE: Proteomic analysis of blood proteins in dried blood spots (DBS) is gaining attention as a possible replacement for measurements in plasma/serum collected by venipuncture. We aimed to develop and provisionally validate a nanoflow LC-PRM-MS method for clinical use. EXPERIMENTAL DESIGN: We used Skyline to develop a nanoflow LC-PRM-MS method to quantify glycated hemoglobin-β, apolipoprotein A-I, and apolipoprotein B in DBS. Precision, linearity, interferences, and stability were determined and the method was used to analyze samples from 36 human volunteers. The method was compared with clinically validated measurements in paired blood collected via venipuncture. RESULTS: The method was relatively precise for these proteins (10-11% CV) and linear across the normal concentration ranges of these proteins. Interference from high total serum protein concentration (>8 g/dL) was noted for apolipoprotein A-I and apolipoprotein B. Proteins in DBS were stable for 14 days at temperatures below 25°C and trypsinized samples were stable for 48 h at 7°C. There was moderate correlation with clinical methods (r = 0.783-0.858) and significant bias in individual samples. CONCLUSIONS AND CLINICAL RELEVANCE: Although the method had adequate precision and linearity for a biomarker, the accuracy compared with clinically validated assays raises concerns regarding the use of DBS compared with venipuncture for clinical use.
PURPOSE: Proteomic analysis of blood proteins in dried blood spots (DBS) is gaining attention as a possible replacement for measurements in plasma/serum collected by venipuncture. We aimed to develop and provisionally validate a nanoflow LC-PRM-MS method for clinical use. EXPERIMENTAL DESIGN: We used Skyline to develop a nanoflow LC-PRM-MS method to quantify glycated hemoglobin-β, apolipoprotein A-I, and apolipoprotein B in DBS. Precision, linearity, interferences, and stability were determined and the method was used to analyze samples from 36 human volunteers. The method was compared with clinically validated measurements in paired blood collected via venipuncture. RESULTS: The method was relatively precise for these proteins (10-11% CV) and linear across the normal concentration ranges of these proteins. Interference from high total serum protein concentration (>8 g/dL) was noted for apolipoprotein A-I and apolipoprotein B. Proteins in DBS were stable for 14 days at temperatures below 25°C and trypsinized samples were stable for 48 h at 7°C. There was moderate correlation with clinical methods (r = 0.783-0.858) and significant bias in individual samples. CONCLUSIONS AND CLINICAL RELEVANCE: Although the method had adequate precision and linearity for a biomarker, the accuracy compared with clinically validated assays raises concerns regarding the use of DBS compared with venipuncture for clinical use.
Authors: Andrew N Hoofnagle; Jessica O Becker; Michael N Oda; Giorgio Cavigiolio; Philip Mayer; Tomas Vaisar Journal: Clin Chem Date: 2012-02-03 Impact factor: 8.327
Authors: Babylakshmi Muthusamy; G Hanumanthu; Shubha Suresh; B Rekha; D Srinivas; L Karthick; B M Vrushabendra; Salil Sharma; Goparani Mishra; Pritam Chatterjee; K S Mangala; H N Shivashankar; K N Chandrika; Nandan Deshpande; M Suresh; N Kannabiran; Vidya Niranjan; Anuradha Nalli; T S Keshava Prasad; K S Arun; Raghunath Reddy; Sreenath Chandran; Trafina Jadhav; D Julie; M Mahesh; S Lynate John; Kshitish Palvankar; D Sudhir; P Bala; N S Rashmi; G Vishnupriya; Kaushik Dhar; S Reshma; Raghothama Chaerkady; T K B Gandhi; H C Harsha; S Sujatha Mohan; Krishna S Deshpande; Malabika Sarker; Akhilesh Pandey Journal: Proteomics Date: 2005-08 Impact factor: 3.984
Authors: Carmen Perich; Joana Minchinela; Carmen Ricós; Pilar Fernández-Calle; Virtudes Alvarez; María Vicenta Doménech; Margarita Simón; Carmen Biosca; Beatriz Boned; José Vicente García-Lario; Fernando Cava; Pilar Fernández-Fernández; Callum G Fraser Journal: Clin Chem Lab Med Date: 2015-02 Impact factor: 3.694
Authors: N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh Journal: Lancet Date: 2010-06-26 Impact factor: 202.731
Authors: Graziella E Ronsein; Nathalie Pamir; Priska D von Haller; Daniel S Kim; Michael N Oda; Gail P Jarvik; Tomas Vaisar; Jay W Heinecke Journal: J Proteomics Date: 2014-10-31 Impact factor: 4.044
Authors: Steven A Carr; Susan E Abbatiello; Bradley L Ackermann; Christoph Borchers; Bruno Domon; Eric W Deutsch; Russell P Grant; Andrew N Hoofnagle; Ruth Hüttenhain; John M Koomen; Daniel C Liebler; Tao Liu; Brendan MacLean; D R Mani; Elizabeth Mansfield; Hendrik Neubert; Amanda G Paulovich; Lukas Reiter; Olga Vitek; Ruedi Aebersold; Leigh Anderson; Robert Bethem; Josip Blonder; Emily Boja; Julianne Botelho; Michael Boyne; Ralph A Bradshaw; Alma L Burlingame; Daniel Chan; Hasmik Keshishian; Eric Kuhn; Christopher Kinsinger; Jerry S H Lee; Sang-Won Lee; Robert Moritz; Juan Oses-Prieto; Nader Rifai; James Ritchie; Henry Rodriguez; Pothur R Srinivas; R Reid Townsend; Jennifer Van Eyk; Gordon Whiteley; Arun Wiita; Susan Weintraub Journal: Mol Cell Proteomics Date: 2014-01-17 Impact factor: 5.911
Authors: Jennifer K Pai; Leah E Cahill; Frank B Hu; Kathryn M Rexrode; Joann E Manson; Eric B Rimm Journal: J Am Heart Assoc Date: 2013-03-22 Impact factor: 5.501
Authors: Dana Boyd Barr; Kurunthachalam Kannan; Yuxia Cui; Lori Merrill; Lauren M Petrick; John D Meeker; Timothy R Fennell; Elaine M Faustman Journal: Environ Res Date: 2021-01-25 Impact factor: 6.498
Authors: Azad Eshghi; Adam J Pistawka; Jun Liu; Michael Chen; Nicholas J T Sinclair; Darryl B Hardie; Monica Elliott; Lei Chen; Rachael Newman; Yassene Mohammed; Christoph H Borchers Journal: Mol Cell Proteomics Date: 2020-01-02 Impact factor: 5.911